Abstract
This article provides a formal correction to previously published research regarding the synergistic role of the molecular chaperones DNAJB6 and Hsp70 in inhibiting $\alpha$-synuclein aggregation. The correction addresses an accidental F46S mutation in the DNAJB6b construct used during the original study. New experimental data demonstrate that this mutation is functionally silent, as the protein retains its correct cellular localization and its ability to suppress protein clumping. These findings confirm that the original conclusions of the paper remain valid.
Introduction
The aggregation of the protein $\alpha$-synuclein is a central pathological feature of neurodegenerative disorders, most notably Parkinson’s disease. Understanding the cellular mechanisms that prevent this aggregation is critical for developing therapeutic strategies. The original study explored how the chaperone proteins DNAJB6 and Hsp70 cooperate to maintain proteostasis by preventing $\alpha$-synuclein from forming toxic aggregates.
Following publication, it was discovered that the cDNA for the DNAJB6b variant used in the experiments contained a random mutation (a TTC to TCC transition), resulting in a phenylalanine-to-serine substitution at position 46 (F46S). Because the J-domain of DNAJB6 is crucial for its interaction with Hsp70, the authors conducted additional experiments to ensure this mutation did not artifactually influence the reported results.
Validating the DNAJB6b (F46S) Construct
To determine if the F46S mutation altered the chaperone's function, the authors performed a rescue experiment using HEK293T cells in which the native DNAJB6 had been knocked out (KO). By introducing the mutated GFP-DNAJB6b construct into these KO cells, the researchers could observe whether the protein still performed its primary functions: proper intracellular localization and suppression of $\alpha$-synuclein aggregation.
The experimental setup utilized multi-channel fluorescence microscopy to track the GFP-tagged chaperone and the $\alpha$-synuclein (tagged with DsRed). This allowed for both qualitative visual confirmation of protein interaction and quantitative analysis of aggregation rates across multiple independent trials ($n=3$).
Experimental Results
The results of the validation study, presented in Figure 1, confirm that the F46S mutation does not impair the chaperone's activity.
As shown in the bar graph (Figure 1A), the percentage of cells containing visible $\alpha$-synuclein aggregates remained very low, approximately 4.5%, when the mutated DNAJB6b was present. This level of suppression is consistent with the potent anti-aggregation activity reported in the original paper. Furthermore, the microscopy images (Figure 1B) demonstrate that the GFP-DNAJB6b (F46S) protein localizes correctly within the cell and overlaps with the target $\alpha$-synuclein, indicating that its ability to interact with its environment and other chaperones like Hsp70 remains intact.
Conclusion
The additional control data provided in this correction successfully address the concerns regarding the accidental F46S mutation. The evidence clearly shows that the mutation is functionally silent in the context of $\alpha$-synuclein aggregation suppression in HEK293T cells. Consequently, the core scientific claim of the original study—that DNAJB6 and Hsp70 work in tandem to prevent the formation of toxic protein aggregates—is upheld and remains a robust contribution to the field of neurodegeneration research.
Summary updated